UBS upgraded ResMed (RMD) to Buy from Neutral with a $290 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on RMD: ResMed price target raised to $280 from $266 at KeyBanc ResMed price target raised to $260 from $252 at Piper Sandler ResMed price target raised to A$41 from A$38 at Citi ResMed Inc. Reports Strong Q2 2025 Growth ResMed reports Q2 EPS $2.43, consensus $2.31
